Further specificity characterization of von Willebrand factor inhibitors developed in two patients with severe von Willebrand disease.
Circulating inhibitors against von Willebrand factor (vWF) that show the properties of heterologous IgG antibodies have been described in a few patients with severe von Willebrand disease (vWD). The present study provides further characterization of inhibitors from two patients with severe vWD. Inhibitors in both, like polyclonal rabbit antibody, detected all sizes of multimers and the complex structure of each multimer from platelets and plasma of normal individuals as well as from plasma of patients with IIA, IIB, and IIC vWD. Both inhibitors and the rabbit antibody reacted mainly with the intact 225-Kd vWF subunit and the 189-H and 140-Kd fragments in contrast to monoclonal antibodies specific for vWF fragments that detected a higher relative proportion of 176-Kd fragment. Furthermore, all these antibodies recognized fragment III, although one inhibitor and rabbit polyclonal antibody reacted poorly and the other inhibitor did not react at all with reduced fragment II of vWF digested with Staphylococcus aureus V-8 protease. These data suggest that although human inhibitors from severe vWD patients may behave, to some extent, as polyclonal heterologous antibodies against native vWF, the former show striking differences in their target specificity as well as a much broader specificity than that described for human factor VIII inhibitors.
López-Fernández
M F
MF
Department of Hematology, Hospital Juan Canalejo, La Coruña, Spain.
Martin
R
R
López-Berges
C
C
Ramos
F
F
Bosch
N
N
Batlle
J
J
D000328:Adult; D000910:Antibodies, Heterophile / Q000302:isolation & purification / Q000502:physiology; D001667:Binding, Competitive; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000302:isolation & purification* / Q000502:physiology; D046911:Macromolecular Substances; D008970:Molecular Weight; D010974:Platelet Aggregation; D012310:Ristocetin; D014842:von Willebrand Diseases / Q000097:blood*; D014841:von Willebrand Factor / Q000037:antagonists & inhibitors* / Q000276:immunology
D000910:Antibodies, Heterophile; D007074:Immunoglobulin G; D046911:Macromolecular Substances; D014841:von Willebrand Factor; D012310:Ristocetin